Back to top

TGA approval of Gilenya® (fingolimod) as first licensed oral treatment for paediatric MS

2 May 2019

On Wednesday 1 May 2019, Novartis announced that the Therapeutic Goods Administration (TGA) has approved Gilenya® (fingolimod) for the treatment of children and adolescents 10-17 years old with relapsing forms of multiple sclerosis.

The registration makes Gilenya the first licenced disease-modifying treatment for children and adolescents in Australia.

Channel 7 News reported the announcement, and spoke to our CEO Deidre Mackechnie who said, “children with MS (will be able to) take a disease-modifying therapy that manages their disease (and) symptoms, slows the progression and (this) is going to have an enormous impact on their life.”

To read Novartis’ media release visit:

We will keep you posted as further details come to hand.

(We will be updating our treatment sheet and treatment summary in the following days.)